Treatment details of 91 patients with MMM who underwent LT
Treatment details . | No. (%) . |
|---|---|
| Supportive care only, transfusions ± hydroxyurea | 48 (53) |
| Noninduction chemotherapy | 19 (21) |
| Weekly vincristine, 2 mg/m2/weekly | 9 (47) |
| Oral alkylators such as melphalan or busulfan | 3 (16) |
| Low-dose cytarabine, subcutaneous | 2 (11) |
| Oral etoposide | 1 (5) |
| Other | 4 (21) |
| Induction chemotherapy | 24 (26) |
| Continuous infusion cytarabine, 5-7 d, plus anthracycline, 2-3 d | 18 (75) |
| High-dose cytarabine, greater than 1000 mg/m2/dose | 3 (13) |
| Mitoxantrone, VP-16, high-dose cytarabine | 3 (13) |
| Gemtuzumab | 3 (13) |
Treatment details . | No. (%) . |
|---|---|
| Supportive care only, transfusions ± hydroxyurea | 48 (53) |
| Noninduction chemotherapy | 19 (21) |
| Weekly vincristine, 2 mg/m2/weekly | 9 (47) |
| Oral alkylators such as melphalan or busulfan | 3 (16) |
| Low-dose cytarabine, subcutaneous | 2 (11) |
| Oral etoposide | 1 (5) |
| Other | 4 (21) |
| Induction chemotherapy | 24 (26) |
| Continuous infusion cytarabine, 5-7 d, plus anthracycline, 2-3 d | 18 (75) |
| High-dose cytarabine, greater than 1000 mg/m2/dose | 3 (13) |
| Mitoxantrone, VP-16, high-dose cytarabine | 3 (13) |
| Gemtuzumab | 3 (13) |